Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
BBIO

BBIO - Bridgebio Pharma Inc Stock Price, Fair Value and News

33.99USD+0.39 (+1.16%)Market Closed
Watchlist

Market Summary

USD33.99+0.39
Market Closed
1.16%

BBIO Alerts

  • 1 major insider buys and 1 major insider sales recently.

BBIO Stock Price

View Fullscreen

BBIO RSI Chart

BBIO Valuation

Market Cap

6.0B

Price/Earnings (Trailing)

-9.54

Price/Sales (Trailing)

60.35

Price/Free Cashflow

-11.25

BBIO Price/Sales (Trailing)

BBIO Profitability

Operating Margin

97.73%

Return on Equity

-42.72%

Return on Assets

-114.11%

Free Cashflow Yield

-8.89%

BBIO Fundamentals

BBIO Revenue

BBIO Earnings

Earnings (TTM)

-623.5M

Earnings Growth (Yr)

-28.03%

Earnings Growth (Qtr)

-11.69%

Breaking Down BBIO Revenue

Last 7 days

8.0%

Last 30 days

-3.8%

Last 90 days

27.2%

Trailing 12 Months

226.1%

How does BBIO drawdown profile look like?

BBIO Financial Health

Current Ratio

3.32

Debt/Equity

0.3

Debt/Cashflow

-1.19

BBIO Investor Care

Shares Dilution (1Y)

16.24%

Diluted EPS (TTM)

-3.95

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20230000
202279.3M88.8M98.4M107.9M
202123.6M39.0M54.3M69.7M
202032.5M24.4M16.3M8.2M
201900040.6M

Tracking the Latest Insider Buys and Sells of Bridgebio Pharma Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Feb 16, 2024
homcy charles j
sold (taxes)
-56,149
37.21
-1,509
-
Feb 16, 2024
homcy charles j
acquired
-
-
3,760
-
Feb 16, 2024
kumar neil
sold (taxes)
-1,783,180
37.21
-47,922
ceo and president
Feb 16, 2024
stephenson brian c
acquired
-
-
44,996
secretary, treasurer & cfo
Feb 16, 2024
kumar neil
acquired
-
-
102,249
ceo and president
Feb 16, 2024
stephenson brian c
sold (taxes)
-703,976
37.21
-18,919
secretary, treasurer & cfo
Feb 15, 2024
valantine hannah
sold
-110,041
37.75
-2,915
-
Feb 15, 2024
valantine hannah
acquired
24,631
8.45
2,915
-
Jan 16, 2024
valantine hannah
acquired
24,631
8.45
2,915
-
Jan 16, 2024
valantine hannah
sold
-110,683
37.97
-2,915
-

1–10 of 50

Which funds bought or sold BBIO recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 20, 2024
Quarry LP
new
-
50,463
50,463
0.01%
Feb 20, 2024
EVENTIDE ASSET MANAGEMENT, LLC
unchanged
-
10,037,000
28,942,300
0.47%
Feb 16, 2024
GSA CAPITAL PARTNERS LLP
sold off
-100
-2,270,000
-
-%
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
added
962
24,944,000
26,579,000
-%
Feb 15, 2024
SPHERA FUNDS MANAGEMENT LTD.
reduced
-18.35
2,278,420
11,390,200
1.83%
Feb 15, 2024
Farther Finance Advisors, LLC
added
1,820
3,744
3,876
-%
Feb 15, 2024
BARCLAYS PLC
added
54.13
17,259,000
29,955,000
0.01%
Feb 15, 2024
JANE STREET GROUP, LLC
reduced
-25.48
1,177,950
9,544,680
-%
Feb 15, 2024
Exome Asset Management LLC
new
-
2,628,610
2,628,610
2.60%
Feb 15, 2024
Financial Gravity Asset Management, Inc.
unchanged
-
-
41.00
-%

1–10 of 34

Are Funds Buying or Selling BBIO?

Are funds buying BBIO calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own BBIO
No. of Funds

Unveiling Bridgebio Pharma Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 16, 2024
kumar neil
5.59%
9,959,504
SC 13G/A
Feb 13, 2024
vanguard group inc
7.36%
12,800,294
SC 13G/A
Jan 29, 2024
blackrock inc.
5.8%
10,156,773
SC 13G/A
Jan 23, 2024
state street corp
2.92%
5,086,899
SC 13G/A
Nov 22, 2023
viking global investors lp
15.7%
25,120,991
SC 13D/A
Jul 20, 2023
viking global investors lp
15.7%
25,120,991
SC 13D/A
Feb 14, 2023
kumar neil
6.42%
9,823,908
SC 13G/A
Feb 09, 2023
vanguard group inc
7.09%
10,591,455
SC 13G/A
Feb 08, 2023
state street corp
5.92%
8,844,943
SC 13G
Feb 01, 2023
blackrock inc.
6.6%
9,834,401
SC 13G/A

Recent SEC filings of Bridgebio Pharma Inc

View All Filings
Date Filed Form Type Document
Feb 22, 2024
10-K
Annual Report
Feb 22, 2024
8-K
Current Report
Feb 21, 2024
4
Insider Trading
Feb 21, 2024
4
Insider Trading
Feb 21, 2024
4
Insider Trading
Feb 20, 2024
4
Insider Trading
Feb 16, 2024
SC 13G/A
Major Ownership Report
Feb 15, 2024
144
Notice of Insider Sale Intent
Feb 13, 2024
4
Insider Trading
Feb 13, 2024
5
Insider Trading

What is the Fair Value of BBIO?

Loading...
Disclaimer: Conduct thorough research and seek guidance from a certified financial advisor prior to finalizing any investment choices.

Peers (Alternatives to Bridgebio Pharma Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
36.8B
6.8B
-16.59% -47.80%
-7.82
5.38
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
19.9B
1.8B
-23.99% -31.71%
-45.13
10.87
76.23% 61.08%
17.2B
2.3B
-4.89% -18.90%
116.89
7.44
15.05% 75.21%
13.6B
3.7B
-7.62% -26.87%
22.76
3.68
8.87% 75.42%
MID-CAP
8.1B
272.9M
-2.06% 34.31%
-13.4
29.75
141.38% 4.43%
6.0B
-
-3.85% 226.12%
-9.54
60.35
54.84% -25.61%
4.1B
631.9M
-12.60% 32.37%
-27.34
6.44
23.54% 31.53%
3.9B
240.7M
-19.08% -10.99%
-13.19
16.26
-1.03% -92.09%
3.7B
270.6M
8.92% 47.81%
-15.63
13.81
440.80% -27.84%
SMALL-CAP
1.5B
348.4M
-3.38% -9.50%
24.15
4.3
81.69% -7.29%
629.6M
1.0B
-9.17% -57.89%
-1.15
0.6
-43.15% 58.48%
179.0M
4.9M
-14.18% -58.18%
-1.09
36.62
-57.57% 50.48%
114.7M
881.7K
289.54% 381.25%
-2.42
112.79
-77.61% -13.74%
4.2M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

Bridgebio Pharma Inc News

Latest updates
MarketBeat10 hours ago
The Washington Post22 Feb 202404:04 pm
Zacks Investment Research22 Feb 202401:14 pm

Bridgebio Pharma Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q3
Revenue-------10860.0013.002.0054.0027.000.008.0013.0017.0022.0027.00
Cost Of Revenue0%1.001.001.00-1.001.001.00-----------
Costs and Expenses10.7%179162148128131129154175179152148168128128125---
Operating Expenses------------16812812812510292.0081.00
  S&GA Expenses33.0%48.0036.0036.0031.0032.0031.0036.0044.0055.0046.0046.0045.0037.0036.0038.0034.0035.0023.00
  R&D Expenses4.1%13012510793.0091.0093.0010810812210410212390.0092.0087.0068.0057.0055.00
EBITDA Margin---------7.97*10.11*14.03*23.26*65.90*7.19*7.63*7.41*7.35*1.66*
Interest Expenses-0.2%20.0020.0021.0020.0020.0020.0020.0020.0015.0011.0011.0010.0011.0011.0011.004.003.002.00
EBT Margin---------7.25*9.30*12.97*21.40*61.28*6.57*7.12*7.12*7.12*1.58*
Net Income100.0%--179-160-142-140-140-2.56-201-152-161-102-171-135-130-136-104-84.15-60.66
Net Income Margin0%-5.78*-5.78*-5.41*-3.95*-4.49*-5.04*-5.82*-7.78*-8.41*-10.47*-13.81*-24.24*------
Free Cashflow14.0%-125-145-113-144-94.04-135-32.85-161-136-128-94.00-152------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets-16.6%5466555046266237298628131,0137821,0811,093704788905990632641582523465
  Current Assets-18.7%4785884335535496427717168896409109456437458629255695582.00-445
    Cash Equivalents-25.6%376505302407377483470372394180378471356367541757364414294373436
  Net PPE-4.8%12.0012.0013.0014.0015.0016.0017.0017.0030.0028.0026.0023.0020.0016.0016.0016.006.003.002.00-2.00
Liabilities2.2%1,8891,8491,8531,8391,8681,8591,8771,8541,8781,5171,5371,48159656957853815611610797.0088.00
  Current Liabilities35.6%14410611097.0012111914110313596.0013295.0096.0076.0093.0065.0060.0040.001.00-33.00
  Long Term Debt-100.0%-442440436431--43443110310391.0092.0093.0093.0092.0092.0075.0075.00-55.00
    LT Debt, Non Current1.1%446442440436431--43443110310391.0092.0093.0093.0092.0092.0075.0075.00-55.00
Shareholder's Equity-100.0%-1,4601,1281,107939917893868842821800767106216326449474522211310377
  Retained Earnings-7.0%-2,560-2,392-2,215-2,057-1,918-1,780-1,643-1,633-1,436-1,289-1,133-1,037-888-768-652-531-440-366-306-240-179
  Additional Paid-In Capital1.5%1,4811,4601,1281,1079399178938688428218007671,0211,007993987848826469493494
Shares Outstanding0.5%175174161160151147147146147147143139---------
Minority Interest-9.4%11.0012.0012.0012.0011.0010.0012.00-0.033.005.007.006.0048.0052.0060.0068.0065.0062.0048.0058.0062.00
Float-------977---5,000---0.00------
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations14.1%-124,819-145,226-113,353-144,322-93,243-135,163-30,453-160,635-133,895-121,561-91,713-150,765-96,261-131,684-87,849-83,920-76,203-49,996-68,248-59,140-46,414
  Share Based Compensation63.8%37,02522,60027,17821,90721,78917,36128,28724,12219,77416,04230,11233,57712,14617,69918,39210,22210,0075,7773,3582,2323,113
Cashflow From Investing-100.2%-66.0037,6824,11912,29817,965146,857149,702138,62321,80058,968458-282,05283,018-45,050-128,98438,023-16,901-197,342-583-2,427-3,599
Cashflow From Financing-101.5%-4,523307,040-1,231150,2496,3771,445-20,796-160325,381-135,456-1,391547,9124,5312,782703439,17342,904367,508-9,969-1,651274,174
  Dividend Payments--------------------997-
  Buy Backs---------1,542143,1505,30850,000---75,000-----

BBIO Income Statement

2023-12-31
Consolidated Statements of Operations - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Statement [Abstract]   
Revenue$ 9,303$ 77,648$ 69,716
Operating costs and expenses:   
Cost of revenue2,4463,4343,114
Research and development455,711399,462451,024
Selling, general and administrative150,590143,189192,210
Restructuring, impairment and related charges7,92643,7650
Total operating costs and expenses616,673589,850646,348
Loss from operations(607,370)(512,202)(576,632)
Other income (expense), net:   
Interest income18,0387,5421,133
Interest expense(81,289)(80,438)(46,778)
Gain from sale of priority review voucher, net0107,9460
Other income (expense), net17,370(7,500)35,823
Total other income (expense), net(45,881)27,550(9,822)
Net loss(653,251)(484,652)(586,454)
Net loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests10,0493,46923,915
Net loss attributable to common stockholders of BridgeBio$ (643,202)$ (481,183)$ (562,539)
Net loss per share attributable to common stockholders of BridgeBio, basic$ (3.95)$ (3.26)$ (3.9)
Net loss per share attributable to common stockholders of BridgeBio, diluted$ (3.95)$ (3.26)$ (3.9)
Weighted-average shares used in computing net loss per share attributable to common stockholders of BridgeBio, basic162,791,511147,473,076144,356,619
Weighted-average shares used in computing net loss per share attributable to common stockholders of BridgeBio, diluted162,791,511147,473,076144,356,619

BBIO Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 375,935$ 376,689
Marketable securities051,580
Investment in equity securities58,94943,653
Receivable from licensing and collaboration agreements1,75117,079
Restricted cash16,65337,930
Prepaid expenses and other current assets24,30521,922
Total current assets477,593548,853
Property and equipment, net11,81614,569
Operating lease right-of-use assets8,02710,678
Intangible assets, net26,31928,712
Other assets22,62520,224
Total assets546,380623,036
Current liabilities:  
Accounts payable10,65511,558
Accrued compensation and benefits57,37031,256
Accrued research and development liabilities29,76539,803
Operating lease liabilities, current portion4,1283,675
Deferred revenue, current portion6,0968,156
Accrued professional and other accrued liabilities35,83026,980
Total current liabilities143,844121,428
Term loan, net446,445430,993
Operating lease liabilities, net of current portion8,98112,274
Other long-term liabilities9,36126,643
Total liabilities1,888,9151,867,960
Commitments and contingencies (Note 9)
Redeemable convertible noncontrolling interests478(1,589)
Stockholders' deficit:  
Undesignated preferred stock, $0.001 par value; 25,000,000 shares authorized; no shares issued and outstanding
Common stock, $0.001 par value; 500,000,000 shares authorized; 181,274,712 shares issued and 175,082,951 shares outstanding as of December 31, 2023, 156,817,333 shares issued and 150,625,572 shares outstanding as of December 31, 2022181157
Treasury stock, at cost; 6,191,761 shares as of December 31, 2023 and December 31, 2022(275,000)(275,000)
Additional paid-in capital1,481,032938,703
Accumulated other comprehensive income (loss)31(328)
Accumulated deficit(2,560,501)(1,918,149)
Total BridgeBio stockholders' deficit(1,354,257)(1,254,617)
Noncontrolling interests11,24411,282
Total stockholders' deficit(1,343,013)(1,243,335)
Total liabilities, redeemable convertible noncontrolling interests and stockholders' deficit546,380623,036
2029 Notes  
Current liabilities:  
Notes, net736,905734,988
2027 Notes  
Current liabilities:  
Notes, net$ 543,379$ 541,634
BBIO
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.
 CEO
 WEBSITEwww.bridgebio.com
 EMPLOYEES392

Bridgebio Pharma Inc Frequently Asked Questions


What is the ticker symbol for Bridgebio Pharma Inc? What does BBIO stand for in stocks?

BBIO is the stock ticker symbol of Bridgebio Pharma Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Bridgebio Pharma Inc (BBIO)?

As of Fri Feb 23 2024, market cap of Bridgebio Pharma Inc is 5.95 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BBIO stock?

You can check BBIO's fair value in chart for subscribers.

What is the fair value of BBIO stock?

You can check BBIO's fair value in chart for subscribers. The fair value of Bridgebio Pharma Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Bridgebio Pharma Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BBIO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Bridgebio Pharma Inc a good stock to buy?

The fair value guage provides a quick view whether BBIO is over valued or under valued. Whether Bridgebio Pharma Inc is cheap or expensive depends on the assumptions which impact Bridgebio Pharma Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BBIO.

What is Bridgebio Pharma Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Feb 23 2024, BBIO's PE ratio (Price to Earnings) is -9.54 and Price to Sales (PS) ratio is 60.35. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BBIO PE ratio will change depending on the future growth rate expectations of investors.